Placebo | 50,000 | 100,000 | p-value | |
---|---|---|---|---|
Baseline (n = 59) | ||||
Mean 25-OHD, unadjusted | ||||
serum collection at -3 to 0 days, n = 34 |
58.7 (43.4-74.0) n = 7 |
52.3 (37.4-67.2) n = 14 |
44.3 (30.8-57.8) n = 13 | 0.39 |
serum collection at days 1-3, n = 25 |
41.6 (29.3-53.9) n = 11 |
59.0 (28.4-89.6) n = 6 |
76.0 (49.1-102.8) n = 8 | 0.03† |
Mean 25-OHD, adjusted for time to measure, n = 59‡ |
46.7 (34.8-58.6) n = 18) |
53.5 (42.3-64.8) n = 20 |
58.4 (47.3-69.5) n = 21 | 0.37 |
4-week (n = 50) | ||||
Mean 25-OHD, unadjusted |
69.8 (59.8-79.8) n = 17 |
84.1 (69.3-98.9) n = 17 |
75.6 (67.6-83.6) n = 16 | 0.17 |
Mean 25-OHD, adjusted for time to measure* |
69.3 (58.4-80.2) n = 17 |
84.5 (73.7-95.3) n = 17 |
75.6 (64.5-86.8) n = 16 | 0.15 |
Proportion ≥ 75 nmol/L | 47.1% | 58.8% | 50.0% | 0.76 |
3-month (n = 47) | ||||
Unadjusted |
85.0 (73.6-93.3) n = 17 |
85.2 (74.5-95.9) n = 12 |
74.3 (66.1-82.5) n = 18 | 0.17 |
Mean 25-OHD, adjusted for time to measure** |
86.7 (77.6-95.9) n = 17 |
84.2 (73.6-94.9) n = 12 |
73.3 (64.5-82.1) n = 18 | 0.09 |
Proportion ≥ 75 nmol/L | 76.5% | 75% | 44.4% | 0.09 |